Concord Biotech's Unit-II clears Kenya and Uganda drug inspection

25 Jun 2026via NSE FilingSource

English हिंदी తెలుగు தமிழ்ಕನ್ನಡ मराठी বাংলা ગુજરાતી

Concord Biotech's Unit-II clears Kenya and Uganda drug inspection. The company announced that the Pharmacy and Poisons Board (PPB) of Kenya and the National Drug Authority (NDA) of Uganda have completed their inspection of its formulation facility. This regulatory clearance supports export compliance and market access in East Africa. 📊 STOCKS: CONCORDBIO | 🏢 SECTOR: Pharma | #LOWIMPACT #Inspection

#Inspection#Regulatory#Pharma

Stocks mentioned

CONCORDBIOCONCORDBIO

⚠️ This brief is AI-generated from public news sources for informational purposes only. Not investment advice. Always consult a SEBI-registered advisor before trading.

Trade smarter on NSE

Live option chains, FII flows, PCR, AI analysis — for NIFTY, BANKNIFTY & 200+ F&O stocks.

Start for ₹1 →